Collaborating with The Egyptian Drug Authority (EDA) Marcyrl Group launched a new innovative product with several KOLs in dermatology from around Egypt.
The 64th Annual International Congress of The Egyptian Society of Chest Diseases & Tuberculosis 2023
Marcyrl Group contributes significantly to The Egyptian Society of Chest Diseases and Tuberculosis through pharmaceutical products at the 64th Annual International Congress of The Egyptian Society of Chest Diseases & Tuberculosis 2023.
The key stakeholders of Cong DRC visit Marcyrl Group facilities
The key stakeholders in Pharmaceutical Health Authorities in Congo DRC along with key persons from the chamber of commerce and industry explore possibilities to export pharmaceutical products to Congo DRS
Marcyrl Pharmaceutical Industries launched Ruxotop, in the presence of Dr. Tamer Essam - Head of the Egyptian Drug Authority.
World Vitiligo Day aims to raise awareness about vitiligo and dispel myths and misconceptions. Marcyrl contributes to enhanced pharmacy research to provide solutions to healthcare professionals.
Marcyrl is driving innovative synergies to raise the quality of the pharmaceutical sector in Africa and worldwide. Africa Health Excon 2024
Why partner with Marcyrl
A Wide portfolio including a niche in hormonal and respiratory
325 SKUs mainly in chronic disease areas; 300 SKUs in the pipeline
A portfolio spanning 15 TAs, in particular female health/fertility, cardiovascular, urology, neuroscience, gastroenterology, etc.
Niche in novel, high-complexity products (in particular hormonal, respiratory)
Why partner with Marcyrl 22
A Wide portfolio including a niche in hormonal and respiratory
325 SKUs mainly in chronic disease areas; 300 SKUs in the pipeline
A portfolio spanning 15 TAs, in particular female health/fertility, cardiovascular, urology, neuroscience, gastroenterology, etc.
Niche in novel, high-complexity products (in particular hormonal, respiratory)
Why partner with Marcyrl 33
A Wide portfolio including a niche in hormonal and respiratory
325 SKUs mainly in chronic disease areas; 300 SKUs in the pipeline
A portfolio spanning 15 TAs, in particular female health/fertility, cardiovascular, urology, neuroscience, gastroenterology, etc.
Niche in novel, high-complexity products (in particular hormonal, respiratory)
